

Reduce of AT-LDL

Study Protocol

Study design: Two arms, randomized double-blind placebo-controlled trial

Subjects: 39 patients with stages I–II COPD according to the Japanese Respiratory Society criteria (age : 20–85 years old)

Intake: THERACURMIN® 90mg x 2 /day, 24 weeks

THERACURMIN® ingestion reduced the level of atherosclerotic α 1-Antitrypsin–low-density lipoprotein (AT-LDL).

